Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 239

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 9
Chunk 239
---
 under the Lake Street Sales Agreement, including ordinary shares previously sold, to $4,500,000. As of December 31, 2024, we have
issued approximately 10,000 ordinary shares for gross proceeds of approximately $85,000 under the Lake Street Sales Agreement.

Information on that transaction is set forth in this Annual Report
under “ Item 5. Operating and Financial Review and Prospects - B. Liquidity and Capital Resources - Recent Public Offerings
of Ordinary Shares - Cantor Controlled Equity OfferingSMSales Agreement” and is incorporated by reference herein.

2024 Registered Direct Offering and Private
Placement

On August 23, 2024, we entered into the Securities Purchase Agreement,
with the Investor, pursuant to which we agreed to issue and sell to the Investor in a registered direct offering, or the 2024 Offering,
(i) 265,000 ordinary shares, and (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 1,427,308 ordinary shares. The
Pre-Funded Warrants have an exercise price of $0.0001 per ordinary share, are immediately exercisable and may be exercised at any time
until exercised in full.

In a concurrent private placement, or the Private Placement, we
also agreed to sell to the Investor unregistered Series A ordinary warrants to purchase up to 1,692,308 ordinary shares, or the Series
A Warrants, and unregistered Series B ordinary warrants to purchase up to 1,692,308 ordinary shares, or the Series B Warrants. Each ordinary
share (or Pre-Funded Warrant) was sold with one Series A Warrant to purchase one ordinary share and one Series B Warrant to purchase one
ordinary share at a combined purchase price of $3.25. The Series A Warrants have an exercise price of $3.55 per share, are immediately
exercisable upon issuance and will expire five years from issuance. The Series B Warrants have an exercise price of $3.55 per share, are
immediately exercisable upon issuance and will expire eighteen months from issuance. Our total gross proceeds from the 2024 Offering and
the Private Placement were approximately $5.5 million.

We also entered into a letter agreement, or the Placement Agency
Agreement, with A. G. P./Alliance Global Partners, as sole placement agent, or AGP, dated August 23, 2024, pursuant to which AGP agreed